Bigfoot Gets by with a Little Help from Its Friends
Bigfoot BiomedicalÂ is on track to submit itsÂ diabetes technology for FDA clearance this year, and the product could hit the market by year end. It helps that the company has some friends with deep pockets like Abbott and other investors that kicked in a total of $45 million in an initial tranche of a series C financing. Bigfoot's injection-based digitized insulin dosing platform uses aÂ connected insulin pen-based system that integrates Abbottâs FreeStyle Libre glucose sensing technology.
DexCom Gives JPM Attendees Something to Talk About
DexCom plans to doubleÂ capacity for its G6 continued glucose management (CGM) system by the end of 2020 while also moving fo...
MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.